COVID-19: Thoughts while circling the wagons

Compared with regulatory agencies overseas, it is a very long and very expensive proposition to gain FDA approval to market a new drug or device. [...]in the United States we don't have a POC C-reactive protein (CRP) device that could help management of respiratory infections. [...]insurance companies have restricted access to better POC diagnostic studies by refusing to pay for more accurate tests when less-expensive (and less-accurate) tests are covered.